Company Filing History:
3 out of 3 
2 out of 15 Years Active: 2008-2012
Title: Miren Lorea Mendoza Arteche: Innovator in Pharmaceutical Chemistry
Introduction
Miren Lorea Mendoza Arteche is a notable inventor based in Derio, Spain. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative patents. With a total of 3 patents, his work focuses on developing new compounds for medical applications.
Latest Patents
One of his latest patents is titled "Nitrogenated trans-stilbene analogs, method for the obtention and medical applications thereof." This invention pertains to new nitrogenated trans-stilbene compounds, specifically imine, pyrrole, and indole derivatives. The procedures for the preparation and use of these compounds are aimed at creating pharmaceutical compositions for treating and preventing various mammalian diseases, including cancer, fibrosclerosis, and acute/chronic inflammation. These compounds address conditions where oxidative stress and angiogenic responses play a significant role.
Another significant patent is "Inhibitors of the LFA-1/ICAM-1 interaction and uses thereof." This invention focuses on treating disorders mediated by the LFA-1/ICAM-1 molecular interaction. It introduces novel chemical compounds that inhibit this interaction, along with pharmaceutical compositions containing these compounds.
Career Highlights
Miren has worked with several organizations, including Dominion Pharmakine S.L. and the Universidad del País Vasco. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative pharmaceutical solutions.
Collaborations
Miren has collaborated with notable colleagues, including Aizpea Zubia Olascoaga and Fernando Vidal Vanaclocha. These partnerships have enriched his research and expanded the impact of his inventions.
Conclusion
Miren Lorea Mendoza Arteche is a distinguished inventor whose work in pharmaceutical chemistry has the potential to significantly impact medical treatments. His innovative patents reflect a commitment to addressing critical health challenges through scientific advancement.